Literature DB >> 1478629

Growth after radiotherapy and chemotherapy in children with leukemia or lymphoma.

L Thun-Hohenstein1, H Frisch, E Schuster.   

Abstract

The effect of radio- and chemotherapy on auxological parameters was investigated in 30 children treated for acute lymphatic leukemia (ALL) or non-Hodgkins lymphoma (NHL). Growth velocity was decreased during the first year of treatment. Catch-up growth was insufficient during the following years. Thus, the whole group experienced a loss of height of 0.49 +/- 1.1 SD at 6.8 +/- 2.6 years after diagnosis. Height and growth velocity were not different between children who received 18 or 24 Gy cranial irradiation; however, growth velocity was significantly lower in children who were treated for more than 2 years or who had the more intensive chemotherapeutic protocol. Evaluation of the growth hormone (GH) response to pharmacological stimulation revealed reduced GH peaks in 47% of the patients, but there was no correlation of GH peak with growth or treatment parameters. In conclusion, the impairment of growth in children after treatment for ALL or NHL might be related to the intensity and duration of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478629     DOI: 10.1159/000182289

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

Review 1.  Bone growth mechanisms and the effects of cytotoxic drugs.

Authors:  H Robson
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  [The significance of preventive CNS irradiation during antineoplastic therapy in childhood with regard to late odontogenic and mandibulofacial injuries].

Authors:  E A Holtgrave; F Heinze; G Henze
Journal:  Fortschr Kieferorthop       Date:  1995-09

3.  Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.

Authors:  Emma Eriksson; Farasat Zaman; Dionisios Chrysis; Henrik Wehtje; Terhi J Heino; Lars Sävendahl
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.